Eli Lilly and CompanyvsMBX Biosciences

LLY and MBX stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,351.12

Value $1.27T

-2.32%
LLY's page

MBX

MBX Biosciences, Inc.

$53.41

Value $2.5B

+0.60%
MBX's page

Eli Lilly and Company (LLY) has a market value of $1.27T and MBX Biosciences (MBX) $2.5B. Over the last year, with dividends, LLY moved +36.2% and MBX +108.6%. Dividend yield: LLY 0.47%, MBX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LLY$1.27T

    MBX$2.5B

    LLY is 502 times MBX

  • Revenue, 12 months

    LLY$86.5B

    MBX–

  • Net income, 12 months

    LLY$27.6B

    MBX-$145M

  • Operating margin

    LLY–

    MBX–

  • ROIC

    LLY35.5%

    MBX-21.0%

    56.5 points apart

  • P/E

    LLY46.2

    MBX–

  • Dividend yield

    LLY0.5%

    MBX0.0%

    0.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LLY+36.2%

MBX+108.6%

100200DecFebAprJunAugOct
Returns by period
PeriodLLYWith dividendsMBXWith dividends
1 year since November 17, 2025+36.2%Price +35.3%+108.6%Price +108.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LLYEli Lilly and CompanyMBXMBX Biosciences

Valuation

LLYMBX
Valuation
Price$1,351.12$53.41
Market value$1.27T$2.5B
Enterprise value (EV)$1.32T$2.1B
P/E46.2–
P/E, 5-year median49.9–
P/B31.75.4
EV/EBIT37.9–
Free cash flow yield1.5%–

Results and growth

LLYMBX
Results and growth
Revenue, 12 months$86.5B–
Net income, 12 months$27.6B-$145M
Free cash flow, 12 months$19.7B-$99M
Earnings per share, 12 months$30.81-$3.02
Revenue growth, year on year44.7%–
Revenue growth a year, past+21.6%over 5 years–
EPS growth a year, past+27.6%over 5 years–

Margins and returns on capital

LLYMBX
Margins and returns on capital
Gross margin83.6%–
Operating margin––
Net margin31.9%–
ROIC35.5%-21.0%
ROE88.6%-34.9%

Balance sheet

LLYMBX
Balance sheet
Cash$4.9B$482M
Total debt$49.5B$3.3M
Net debt / EBITDA1.2–
Interest cover38.9×–

Dividends and buybacks

LLYMBX
Dividends and buybacks
Dividend yield0.5%–
Dividend per share, 12 months$6.34–
Dividend growth a year, past+15.2%over 5 years–
Buyback yield0.3%0.0%
Shareholder yield0.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LLY or MBX

Didn't find what you were looking for?

Ask us
Which is bigger, Eli Lilly and Company or MBX Biosciences?

By market value, Eli Lilly and Company ($1.27T) is about 502.3 times MBX Biosciences ($2.5B), at today's prices.

How did LLY and MBX stock do over the last 1 years?

Since November 17, 2025, LLY's price moved +35.3% and MBX's +108.6%. With dividends: LLY +36.2% (+36.2% a year), MBX +108.6% (+108.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, LLY or MBX?

The dividend yield at today's price is 0.47% for Eli Lilly and Company and none for MBX Biosciences. Over the last twelve months they paid $6.34 and – per share.

Which is the better investment, Eli Lilly and Company or MBX Biosciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.